Replies to post #110002 on Biotech Values

[bladerunner1717]

10nisman,

I'm not an attorney, although I have been to law school, but I think if TEVA's generic Lovenox never gets approved, TEVA shareholder lawsuits will abound. We'll see, but it will take quite a while.

In a more general sense, I think Israeli conventional business strategy and tactics might get a bit of a comeuppance from the American judicial system. From my perspective here in Hollywood, we've seen unscrupulous Israeli business tactics get a big comeuppance from regulatory agencies here in California (especially the California Labor Board) and the courts as well.

I see MNTA's complaint as a kind of "shot across the bow" at TEVA, alerting them to the fact that their statements about the "imminent approval of Lovenox" are unscrupulous, and they harm not only MNTA shareholders, but create a negative climate for MNTA in pursuing its own business strategy, e.g potential partnership activity on other generic products.


Bladerunner

[RockRat]

I'm not so sure that t-enox is immaterial to Teva from an investor's standpoint. Peter calculated that it would be a 15% bump in their profits (I incorrectly posted .15/share from memory recently; here's the correction):

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=55013723

This is why I, ilpapa, and maybe a few others have been wondering aloud how much trash Teva can talk and for how long before they get sued by shareholders if they fail to get approval.

Regards, RockRat